A Long-term Study to Determine Safety and Efficacy of Dutasteride in Male Subjects With Androgenetic Alopecia
Status:
Completed
Trial end date:
2014-07-19
Target enrollment:
Participant gender:
Summary
This is a multicentre, open-label study to assess the safety, tolerability, and efficacy of
0.5 mg Dutasteride administered once daily for 52 weeks in men with Androgenetic Alopecia
types III vertex, IV and V per the Norwood-Hamilton classification. The study consists of a
Screening Phase (3 weeks prior to Baseline) and a Treatment Phase (52 weeks). A subject who
completes the full course of study treatment and the final study visit (Week 52; Visit 7)
will be considered as study completion.